

Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.

NCT06305390

Status	RECRUITING
Phase	Phase 2
Sponsor	IRCCS San Raffaele
Enrollment	167 participants

Plain Language Summary

This study tests whether a combined PET/MRI scan using a special prostate-targeting tracer (18F-PSMA) can detect clinically significant prostate cancer better or more conveniently than separate imaging tests and biopsies done over multiple visits.

****You may be eligible if...****

- You are a man aged 18 or older
- Your doctor suspects you may have prostate cancer and has recommended a biopsy
- You are physically able to undergo all the procedures in the study
- You can provide written informed consent

****You may NOT be eligible if...****

- You have already been diagnosed with prostate cancer
- You cannot have an MRI scan (for example due to claustrophobia, a pacemaker, or reduced kidney function)
- You have a contraindication to prostate biopsy

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (3)

- Men at least 18 years of age referred with clinical suspicion of prostate cancer candidate for prostate biopsy
- Feasibility to undergo all procedures listed in protocol
- Ability to provide written informed consent

Exclusion (3)

- Prior diagnosis of prostate cancer
- Contraindication to MRI (e.g. claustrophobia, pacemaker, estimated GFR lower or equal to 50mls/min)
- Contraindication to prostate biopsy

Locations (1 total)

U.O. of Nuclear Medicine, Ospedale San Raffaele, Milan, Milano, Italy

<https://clinicaltrials.gov/study/NCT06305390>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).